Results 101 to 110 of about 93,450 (318)

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis [PDF]

open access: yes, 2017
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA-REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure.
De Vecchis   +22 more
core   +1 more source

Obstructive sleep apnea and cardiovascular disease in individuals with metabolic dysfunction‐associated fatty liver disease: A prospective cohort study

open access: yesSleep Research, EarlyView.
Abstract Objective To assess the association between obstructive sleep apnea (OSA) risk levels and major cardiovascular disease (CVD) subtypes in individuals with metabolic dysfunction‐associated fatty liver disease (MAFLD). Methods This cohort study included 128,022 MAFLD participants from the UK Biobank without CVD at baseline.
Haizhen Chen   +4 more
wiley   +1 more source

Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus [PDF]

open access: yes, 2005
Aims/hypothesis: Plasma semicarbazide-sensitive amine oxidase (SSAO) is elevated in patients with type 1 and type 2 diabetes and has been implicated in the pathophysiology of diabetic late complications. The regulation of SSAO production remains unknown.
Agerholm-Larsen, B. (B.)   +6 more
core   +1 more source

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan   +9 more
wiley   +1 more source

Pharmacological effects of raas blockade in ischemic nephropathy [PDF]

open access: yes, 2016
Background: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become increasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the initial step.
Barbano, Biagio   +8 more
core   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy   +10 more
wiley   +1 more source

Parathyroid localization [PDF]

open access: yes, 1986
Twenty-nine consecutive patients with suspected primary hyperparathyroidism were examined preoperatively using ultrasound, sonographically guided fine needle aspiration, and aspirate immunostaining for PTH.
Borisch, B.   +7 more
core   +1 more source

Maternal exercise improves vascular function in hypertensive offspring via A‐kinase anchoring protein 150 gene (Akap5) epigenetic modifications

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Regular physical activity is an effective non‐pharmacological approach to hypertension management and maternal exercise improves offspring cardiovascular health, although mechanisms remain unclear. A‐kinase anchoring protein 150 (AKAP150) targets protein kinase Cα to L‐type Ca2+ channels (CaV1.2), enhancing vascular tone in ...
Fang Qiu   +8 more
wiley   +1 more source

The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction

open access: yesVascular Health and Risk Management, 2008
Paolo Verdecchia1, Fabio Angeli1, Giovanni Mazzotta1, Giorgio Gentile2, Gianpaolo Reboldi21Department of Cardiology, Clinical Research Unit ‘Preventive Cardiology’, Hospital ‘Santa Maria della Misericordia’, and Fondazione Umbra ...
Paolo Verdecchia   +4 more
doaj  

Home - About - Disclaimer - Privacy